<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01607294</url>
  </required_header>
  <id_info>
    <org_study_id>1002-005</org_study_id>
    <nct_id>NCT01607294</nct_id>
  </id_info>
  <brief_title>A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes</brief_title>
  <official_title>A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Esperion Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Esperion Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2 study will asses the LDL-C lowering efficacy of ETC-1002 versus placebo in
      subjects with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assess the LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with type 2 diabetes</measure>
    <time_frame>4 weeks</time_frame>
    <description>evaluate the change in LDL-C from baseline to various time points</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>assess the effect of ETC-1002 versus placebo on glycemic parameters including fasting plasma and postprandial glucose and insulin</measure>
    <time_frame>4 weeks</time_frame>
    <description>evaluate the change in glucose and insulin from baseline to various time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess the effect of ETC-1002 versus placebo on measures of insulin sensitivity in subjects with type 2 diabetes</measure>
    <time_frame>4 weeks</time_frame>
    <description>evaluate the change in HOMA-IR from baseline to various time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess safety using adverse event reports, physical exams, vital signs, ECGs and clinical laboratory parameters</measure>
    <time_frame>4 weeks</time_frame>
    <description>evaluate any changes in safety parameters during the course of the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hyperlipidemia</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>ETC-1002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ETC-1002 daily Weeks 1-2, 80 mg/day; Weeks 3-4, 120 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo daily 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ETC-1002</intervention_name>
    <description>ETC-1002 Daily for 4 weeks</description>
    <arm_group_label>ETC-1002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Daily for 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of type 2 diabetes meeting all of the following:

          -  Minimum 6 month history of diabetes prior to screening visit;

          -  Fasting C-peptide ≥ 0.8 ng/mL at screening visit;

          -  HbA1C at screening visit 7-10%;

          -  Fasting glucose from 140-270 mg/dL on Day -7 following washout of all glucose
             regulating drugs and supplements.

          -  BMI at screening visit from 25-35 kg/m2;

          -  LDL-C at screening ≥ 100 mg/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2012</study_first_submitted>
  <study_first_submitted_qc>May 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2012</study_first_posted>
  <disposition_first_submitted>August 13, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>August 27, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 11, 2015</disposition_first_posted>
  <last_update_submitted>August 27, 2015</last_update_submitted>
  <last_update_submitted_qc>August 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

